000			nab a22 7a 4500
999			_c17477 _d17477
003			PC17477
005			20230524125004.0
008			230524b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_9891 _aVanaclocha Sebastián, Francisco _eDermatología Médico Quirúrgica y Venereología
245	0	0	_aUse of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: A cross-sectional study in clinical practice. _h[artículo]
260			_bThe Journal of dermatological treatment, _c2015
300			_a26(6):502-6.
500			_aFormato Vancouver: Carrascosa JM, Garcia Doval I, Pérez Zafrilla B, Carretero G, Vanaclocha F, Daudén E et al; BIOBADADERM Study Group. Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: A cross-sectional study in clinical practice. J Dermatolog Treat. 2015;26(6):502-6.
501			_aPMID: 25886087
504			_aContiene 26 referencias
520			_aIntroduction: Biologic medications increase dramatically the burden of a chronic and high prevalent disease like psoriasis. The objective of the study was to quantify the use of dose reduction or dose escalation strategies, not reflected in the drug summary of product characteristics, in clinical practice. Methods: An observational, cross-sectional study of a subset of patients from the Spanish Registry for Systemic Treatments in Psoriasis (BIOBADADERM) treated for over six consecutive months with the same biologic agent. Results: The study included 637 patients. At the cut-off date, the initial dose had been reduced in 223 patients (35%; 95% CI: 31.3-38.9%) and escalated in 46 (7.2%; 95% CI: 5.3-9.5%). When compared with the patients treated with standard doses, the patients on reduced doses had a lower PASI score at the cut-off date (a mean 2.6 versus 1; -1.6 points) and exhibited greater improvement in PASI since the start of biologic therapy (mean reduction over baseline 75% versus 87%). By contrast, the patients receiving an escalated dose had higher PASI scores (2.6 versus 8.0) and showed less improvement in PASI (75% versus 46.8%). Conclusion: Off-label doses of biologic agents for psoriasis are frequent in clinical practice. This information is especially relevant for pharmacoeconomic models.
710			_9145 _aServicio de Dermatología Médico-Quirúrgica y Venereología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc17477.pdf _ySolicitar documento
942			_2ddc _cART _n0